Related Experiment Videos
[5-alpha-reductase inhibitors in benign prostatic hyperplasia]
Khirurgiia
|January 1, 1997
Summary
Finasteride treatment for benign prostate hyperplasia (BPH) improved urinary flow and reduced prostate size in most patients. Subjective complaints also decreased, indicating effective conservative management for BPH symptoms.
Area of Science:
- Urology
- Pharmacology
Context:
- Benign prostate hyperplasia (BPH) is a common condition in aging men.
- Conservative treatment options are sought to manage BPH symptoms and improve quality of life.
Purpose:
- To evaluate the efficacy of Finasteride in treating benign prostate hyperplasia.
- To assess changes in subjective complaints, urinary flow, residual urine, and prostate volume.
Summary:
- Sixteen patients with BPH received Finasteride treatment.
- Follow-up assessments included the International Prostate Symptom Score (IPSS), uroflowmetry, residual urine measurement, and echography.
- Positive outcomes were observed in 78% of patients, with a 3.2 ml/sec increase in maximal urinary flow and a 24.5% reduction in prostate volume.
Impact:
- Finasteride demonstrates significant efficacy in improving urinary function and reducing prostate size in BPH patients.
- Alleviation of subjective symptoms was noted in 69% of patients, highlighting its therapeutic value.
- This study supports Finasteride as a viable conservative treatment for benign prostate hyperplasia.